{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T07:56:21Z","timestamp":1767167781053,"version":"build-2238731810"},"reference-count":20,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"unspecified","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2022,3,31]]},"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n                    <jats:title>Case<\/jats:title>\n                    <jats:p>\n                      A 39-year-old man with thymoma-associated acetylcholine receptor antibody myasthenia gravis (MG) presented with fevers, night sweats, abdominal pain and weight loss. Marked splenomegaly and intra-abdominal lymphadenopathy were found. Biopsies confirmed disseminated\n                      <jats:italic>Mycobacterium genavense<\/jats:italic>\n                      infection. Despite antimicrobials and reduced immunosuppressive medications, he worsened. We suspected a thymoma-associated cytokine inhibitory antibody. The addition of subcutaneous interferon-gamma (IFN-\u03b3) induced clinical and radiological improvement. His antimicrobials were able to be ceased. MG remained stable. Subsequent testing demonstrated an endogenous interleukin-12 (IL-12) inhibitor, likely inhibiting the IL-12\/IFN-\u03b3 axis crucial for defence against mycobacterial infections.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This case illustrates the autoimmune manifestations that can occur with thymoma. It illustrates the benefit of exogenous IFN-\u03b3 in overcoming the immune deficit. In this case, its use did not exacerbate existing autoimmune disease or trigger others. We raise awareness of the need to consider cytokine pathway defects as a contributing factor to refractory atypical infections in patients with thymoma-associated MG.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjno-2022-000285","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T11:35:25Z","timestamp":1652873725000},"page":"e000285","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Refractory\n                    <i>Mycobacterium genavense<\/i>\n                    infection secondary to thymoma-associated endogenous IL-12 inhibitor"],"prefix":"10.1136","volume":"4","author":[{"given":"Jessie","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Neurology, Concord Repatriation General Hospital, Concord, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MaiAnh","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Immunology, Concord Repatriation General Hospital, Concord, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Immunology, Concord Repatriation General Hospital, Concord, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine","family":"Cheong","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Microbiology, Concord Repatriation General Hospital, Concord, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Sean Riminton","sequence":"additional","affiliation":[{"name":"Department of Immunology, Concord Repatriation General Hospital, Concord, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Reddel","sequence":"additional","affiliation":[{"name":"Department of Neurology, Concord Repatriation General Hospital, Concord, New South Wales, Australia"},{"name":"Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"2025072811484334000_4.1.e000285.1","doi-asserted-by":"publisher","DOI":"10.1080\/00365549950161907"},{"key":"2025072811484334000_4.1.e000285.2","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1128\/jcm.34.7.1840-1842.1996","article-title":"Mycobacterium genavense infections in PET animals","volume":"34","author":"Kiehn","year":"1996","journal-title":"J Clin Microbiol"},{"key":"2025072811484334000_4.1.e000285.3","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1128\/jcm.33.9.2514-2515.1995","article-title":"Species-Specific Mycobacterium genavense DNA in intestinal tissues of individuals not infected with human immunodeficiency virus","volume":"33","author":"Dumonceau","year":"1995","journal-title":"J Clin Microbiol"},{"key":"2025072811484334000_4.1.e000285.4","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.37.12.3901-3905.1999"},{"key":"2025072811484334000_4.1.e000285.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2012.03817.x"},{"key":"2025072811484334000_4.1.e000285.6","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2000.00730.x"},{"key":"2025072811484334000_4.1.e000285.7","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aau6759","article-title":"Human IFN-\u03b3 immunity to mycobacteria is governed by both IL-12 and IL-23","volume":"3","author":"Mart\u00ednez-Barricarte","year":"2018","journal-title":"Sci Immunol"},{"key":"2025072811484334000_4.1.e000285.8","doi-asserted-by":"publisher","DOI":"10.1172\/JCI4950"},{"key":"2025072811484334000_4.1.e000285.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6101(00)00010-1"},{"key":"2025072811484334000_4.1.e000285.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(99)80055-7"},{"key":"2025072811484334000_4.1.e000285.11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-286161"},{"key":"2025072811484334000_4.1.e000285.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(03)00136-X"},{"key":"2025072811484334000_4.1.e000285.13","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.68.6.3720-3723.2000"},{"key":"2025072811484334000_4.1.e000285.14","doi-asserted-by":"publisher","DOI":"10.1126\/science.280.5368.1435"},{"key":"2025072811484334000_4.1.e000285.15","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1128\/jcm.30.12.3206-3212.1992","article-title":"Laboratory aspects of \"Mycobacterium genavense,\" a proposed species isolated from AIDS patients","volume":"30","author":"Coyle","year":"1992","journal-title":"J Clin Microbiol"},{"key":"2025072811484334000_4.1.e000285.16","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2003.02113.x"},{"key":"2025072811484334000_4.1.e000285.17","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120222"},{"key":"2025072811484334000_4.1.e000285.18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jneuroim.2006.02.012","article-title":"Elevation of IL-12 p40 and its antibody in myasthenia gravis with thymoma","volume":"175","author":"Yoshikawa","year":"2006","journal-title":"J Neuroimmunol"},{"key":"2025072811484334000_4.1.e000285.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199405123301904"},{"key":"2025072811484334000_4.1.e000285.20","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"}],"updated-by":[{"DOI":"10.1136\/bmjno-2022-000285corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000}}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2022-000285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T18:48:47Z","timestamp":1753728527000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2022-000285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,5,18]]},"published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1136\/bmjno-2022-000285"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2022-000285","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}